Ulrich Neumann

Ulrich Neumann
Ulrich Neumann, MBA MSc MA BSc BA, is the Founder and Managing Director at Pharmvivo Ventures, a strategic knowledge and networking platform for b2b exchanges in lifesciences. He also serves as Senior US Director at Certara, where he leads the Access and Commercial Strategy team in New York. Valued at over $5B, Certara is a drug development strategy and software startup listed on Nasdaq. With a dual background in business and public administration, Ulrich works on reimbursement and commercial strategy projects with pharma developers, while also serving as lead for commercial due diligences for private equity clients. His commercial experience …
Ulrich Neumann, MBA MSc MA BSc BA, is the Founder and Managing Director at Pharmvivo Ventures, a strategic knowledge and networking platform for b2b exchanges in lifesciences. He also serves as Senior US Director at Certara, where he leads the Access and Commercial Strategy team in New York. Valued at over $5B, Certara is a drug development strategy and software startup listed on Nasdaq. With a dual background in business and public administration, Ulrich works on reimbursement and commercial strategy projects with pharma developers, while also serving as lead for commercial due diligences for private equity clients.

His commercial experience lies in defining product strategy, value messaging and b2b brand development. The founder of several entrepreneurial ventures, Ulrich most recently led the US division of a global pharma networking platform (now part of Thomson Reuters). He joined Certara in early 2017, having worked on go-to-market projects for over ten years, leading multimillion $ P&Ls and cross-functional academic/commercial teams in Europe and the US. Working in public and corporate affairs, he led strategy projects for multi-national clients in the health, bottled water, energy, and defense industries, serving placements at agencies such as Advice Partners and Hill & Knowlton (WPP), at the President of the EU Parliament as well as on projects funded by France’s Ministry of Foreign Affairs. A frequent expert contributor and conference speaker, Ulrich manages and hosts “The Market Access Radar”, a weekly Certara broadcast on current pharma policy and reimbursement topics.

Ulrich holds an MBA from Imperial College London, an MSc from the London School of Economics and an MA from the University of Southern California, Annenberg School and Marshall School of Business. His undergraduate degrees are in Public Administration (BSc) and Multi-level Governance (BA). The author of two books, he has published various trade articles, whitepapers, reports, and posters on critical pharma and managed care topics. Ulrich is frequently speaking at industry conferences and lectures, such as leading a graduate seminar on clinical trial innovation at Rutgers University Business School (Irvine Center). An active member of AMCP, AMBA, DIA and ISPOR, he is also a nominated Fellow of the Royal Society of Arts and Commerce since 2014.
See more

Articles: Ulrich Neumann

Navigating the Increasingly Stormy Waters of US Market Access 

USA / Certara’s Ulrich Neumann examines some of the major US market access trends of the past few years, including the innovative financing models required for novel therapies, why cost effectiveness considerations are on the rise, and the impact of the drug policy environment on payer sentiments.   The US reimbursement landscape has been shifting rapidly while…

Paying for Cell & Gene Therapy in the USA: Is the Future Already Here?

USA / Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced, the multiple models now under development, and why an open and collaborative approach among US healthcare stakeholders is needed if the significant legal and practical barriers are to be overcome.   The ascent of cell and gene…

A Changing View of Sales In Pharma

Data / New approaches to pharma sales: Marrying data analytics with the art of personal engagement   The lock-down impact for COVID-19 was stark, looking at available March data cuts from IQVIA which signal serious additional healthcare consequences beyond infected patients. A decline of 72% of in-person doctor visits, -70% Rx volume, -70% lab test (excl. COVID-19),…

US Prescription Drug Pricing: “The Times They Are A Changin”

USA / Ulrich Neumann examines the debate around drug pricing in the US and why it is not going away any time soon.   Come senators, congressmen Please heed the call Don’t stand in the doorway Don’t block up the hall For he that gets hurt Will be he who has stalled” Bob Dylan, recorded his iconic…

Can We Afford to Pay for Future Cures?

Opinion / Pharmaceutical innovation is racing ahead of the US health system’s ability to adjust payment models, but innovative concepts are finally emerging. We will have to move beyond siloed thinking to establish them for the sake of getting patients sustainable access to a new wave of transformative cures, argues Ulrich Neumann.   A look at recent…

ICER Strikes Again: Scandal Time?

USA / The US drug-price watchdog, The Institute for Clinical & Economic Review (ICER) recently issued a “Report on Unsupported Price Increases,” picking a number of innovative medicines that it says have seen price hikes without sufficient substantiation. While the study made the headlines, Certara’s Ulrich Neumann calls for some scepticism and asks the question: “How sufficient…

Real World Evidence: From Market Access to Drug Approval?

Opinion / Ulrich Neumann of Certara outlines recent developments in the use of real-world evidence (RWE) and the sizeable impact it stands to make on the global biopharma industry.   While the collection of real-world data is not new, real-world evidence is poised to have a profound impact on the biopharma industry The end of 2018 ushered…

See more